Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

被引：8

作者：

Prat, A. ^{[1
]}

Falato, C. ^{[2
]}

Pare Brunet, L. ^{[3
]}

Martinez Saez, O. ^{[4
]}

Cejalvo Andujar, J. M. ^{[5
]}

Margeli Vila, M. ^{[6
]}

Tolosa, P. ^{[7
]}

Salvador Bofill, F. J. ^{[8
]}

Cruz Jurado, J. ^{[9
]}

Gonzalez-Farre, B. ^{[10
]}

Sanfeliu Torres, E. ^{[10
]}

Ciruelos, E. M. ^{[11
]}

Espinosa-Bravo, M. ^{[12
]}

Izarzugaza Peron, Y. ^{[13
]}

Pernas Simon, S. ^{[14
]}

Esker, S. ^{[15
]}

Fan, P-D. ^{[16
]}

Ferrero Cafiero, J. M. ^{[17
]}

Pascual, T. ^{[18
]}

Oliveira, M. ^{[19
]}

机构：

[1] Hosp Clin Barcelona SOLTI IDIBAPS, Dept Med Oncol, Barcelona, Spain

[2] IDIBAPS August Pi Sunyer Biomed Res Inst, SOLTI Canc Res Grp, Barcelona, Spain

[3] SOLTI Canc Res Grp, Data Management, Barcelona, Spain

[4] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Canc Res Grp, Barcelona, Spain

[5] Hosp Clin Univ Valencia, Dept Med Oncol, SOLTI Canc Res Grp, Valencia, Spain

[6] ICO Inst Catala Oncol Badalona Hosp Univ Germans, Dept Med Oncol, SOLTI Canc Res Grp, Badalona, Spain

[7] Inst Invest Sanitaria Hosp 12 Octubre, Dept Med Oncol, SOLTI Canc Res Grp, Madrid, Spain

[8] Hosp Univ Virgen Valme, Med Oncol, Seville, Spain

[9] Hosp Univ Canarias, Dept Med Oncol, San Cristobal, Spain

[10] Hosp Clin Barcelona, Pathol Dept, SOLTI Canc Res Grp, Barcelona, Spain

[11] Hosp Univ 12 Octubre, Dept Med Oncol, SOLTI Canc Res Grp, Madrid, Spain

[12] Vall dHebron Univ Hosp, Breast Surg Unit, Barcelona, Spain

[13] Hosp Univ Fdn Jimenez Diaz, Dept Oncol, Madrid, Spain

[14] ICO Inst Catala Oncol Hosp Hosp Duran, Dept Med Oncol, SOLTI Canc Res Grp, Lhospitalet De Llobregat, Spain

[15] Daiichi Sankyo Inc, Global Med Dept, Basking Ridge, NJ USA

[16] Daiichi Sankyo Pharma Dev USA, Global Oncol, Edison, NJ USA

[17] SOLTI Canc Res Grp, Dept Clin Res, Barcelona, Spain

[18] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Canc Res Grp, Barcelona, Spain

[19] Vall dHebron Inst Oncol VHIO, SOLTI Canc Res Grp, Breast Canc Unit, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.03.279

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA3

引用

页码：S164 / S164

页数：1

共 50 条

[21] Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2-breast cancer
Corti, Chiara
Chu, Xiangying
Exman, Pedro
Kline, Danielle
Priedigkeit, Nolan
Tayob, Nabihah
Mayer, Erica
Waks, Adrienne
Hughes, Melissa
Giordano, Antonio
Curigliano, Giuseppe
Lin, Nancy
King, Tari
Jeselsohn, Rinath
Dillon, Deborah
Mittendorf, Elizabeth
Tolaney, Sara
CANCER RESEARCH, 2024, 84 (09)
[22] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN HR+/HER2-EARLY STAGE BREAST CANCER
Criscitiello, C.
Wild, R.
Rider, A.
Williams, R.
Mitra, D.
Bambrick, C.
Kurosky, S.
VALUE IN HEALTH, 2020, 23 : S480 - S480
[23] Effect of Neoadjuvant Letrozole and Ribociclib on Nodal Pathologic Response in HR+/Her2-Breast Cancer (FELINE Trial)
Abbassi-Rahbar, Shahrzad
Khan, Qamar J.
Fan, Fang
Gloyeske, Nika C.
Larson, Kelsey E.
Amin, Amanda L.
Balanoff, Christa R.
Kilgore, Lyndsey J.
Sharma, Priyanka
O'Dea, Anne P.
Nye, Lauren
O'Regan, Ruth
Wisinski, Kari B.
Kalinsky, Kevin
Trivedi, Meghna
Bardia, Aditya
Spring, Laura
Ma, Cynthia
Yuan
Mudaranthakam, Dinesh Pal
Wagner, Jamie L.
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S247 - S248
[24] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
Vollbrecht, Claudia
Hoffmann, Inga
Lehmann, Annika
Merkelbach-Bruse, Sabine
Fassunke, Jana
Wagener-Ryczek, Svenja
Ball, Markus
Dimitrova, Lora
Hartmann, Arndt
Stohr, Robert
Erber, Ramona
Weichert, Wilko
Pfarr, Nicole
Bohlmann, Lisa
Jung, Andreas
Dietmaier, Wolfgang
Dietel, Manfred
Horst, David
Hummel, Michael
VIRCHOWS ARCHIV, 2023, 482 (04) : 697 - 706
[25] Treatment of HR+/HER2-breast cancer in urban mainland China: results from the CancerMPact Survey 2019
Murali, Bhavna
Durbin, Laura
Vijaykumar, Sapna
Yang, Linda
Li, Song
Zhao, Linda
Hawthorne, Stephanie
Kanas, Gena
Davis, Christine
Clark, Otavio
BREAST CANCER RESEARCH AND TREATMENT, 2022, 195 (03) : 441 - 451
[26] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
Claudia Vollbrecht
Inga Hoffmann
Annika Lehmann
Sabine Merkelbach-Bruse
Jana Fassunke
Svenja Wagener-Ryczek
Markus Ball
Lora Dimitrova
Arndt Hartmann
Robert Stöhr
Ramona Erber
Wilko Weichert
Nicole Pfarr
Lisa Bohlmann
Andreas Jung
Wolfgang Dietmaier
Manfred Dietel
David Horst
Michael Hummel
Virchows Archiv, 2023, 482 : 697 - 706
[27] TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2-breast cancer
Bardia, Aditya
Jhaveri, Komal
Kalinsky, Kevin
Pernas, Sonia
Tsurutani, Junji
Xu, Binghe
Hamilton, Erika
Im, Seock-Ah
Nowecki, Zbigniew
Sohn, Joohyuk
De Laurentiis, Michelino
Martinez Janez, Noelia
Adamo, Barbara
Lee, Keun Seok
Jung, Kyung Hae
Rubovszky, Gabor
Tseng, Ling-Ming
Lu, Yen-Shen
Yuan, Yuan
Maxwell, Micah J.
Haddad, Vincent
Khan, Sabrina S.
Rugo, Hope S.
Pistilli, Barbara
FUTURE ONCOLOGY, 2024, 20 (08) : 423 - 436
[28] PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2-breast cancer
Teran, Eduardo
Lozano, Rebeca
Rodriguez, Cesar A.
Abad, Mar
Figuero, Luis
Munoz, Jose Antonio
Cigarral, Belen
Rodrigues, Aline
Sancho, Magdalena
Gomez, M. Asuncion
Morchon, Daniel
Montero, Juan Carlos
Sayagues, Jose Maria
Ludena, M. Dolores
Fonseca, Emilio
CANCER MEDICINE, 2024, 13 (17):
[29] A multinational study of real-world treatment patterns among patients with early stage HR+/HER2-breast cancer (BC)
Criscitiello, C.
Spurden, D.
Rider, A.
Williams, R.
Corsaro, M.
Pike, J.
Law, E. H.
ANNALS OF ONCOLOGY, 2020, 31 : S42 - S43
[30] Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
Arter, Zhaohui Liao
Nagasaka, Misako
LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 115 - 121

← 1 2 3 4 5 →